Company news

Dr. Reddy's Laboratories Ltd. news in 2026

Dr. Reddy's Laboratories Ltd.'s news releases, calls and decks from 2026, newest first.

View company

Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 21, 2026, titled "Dr. Reddy s Receives DCGI Approval for Zytorvi® (toripalimab) in Advanced Esophageal Squamous Cell Carcinoma, Its Second Approved Indication in India.".

October 21, 2026

Dr. Reddy's Laboratories Limited has informed the Exchange regarding a press release dated October 07, 2026, titled "Intimation of Earnings call".

October 7, 2026

Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

August 4, 2026

Dr. Reddy's Laboratories Ltd. Press Release Aug 01 2026

August 1, 2026

Dr. Reddy's Laboratories Ltd. Press Release Jul 23 2026

July 22, 2026

Dr. Reddy's Laboratories Ltd. Press Release Jul 13 2026

July 13, 2026

Dr. Reddy's Laboratories Limited Announces Filing of Annual Report on Form 20-F

June 29, 2026

Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F

June 26, 2026

Dr. Reddy’s Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States

June 13, 2026

Annual Report for Fiscal Year Ending March 31, 2026 (Form 20-F)

May 29, 2026

Press Release May 28 2026

May 28, 2026

Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada

May 16, 2026

Press Release May 16 2026

May 15, 2026

Press Release May 12 2026

May 12, 2026

Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada

April 29, 2026

Press Release Apr 24 2026

April 24, 2026

Press Release Mar 21 2026

March 21, 2026

Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

February 23, 2026

Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept

February 20, 2026

Press Release Feb 18 2026

February 18, 2026

Dr. Reddy's Laboratories: . Reddy’s Q3 & 9MFY26 Financial Results

January 21, 2026

Dr. Reddy's announces the first-to-market launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the generic equivalent of Extra-Strength Pataday Once Daily Relief, in the U.S.

January 15, 2026

Press Release Jan 14 2026

January 14, 2026

Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.

January 14, 2026

Press Release Jan 08 2026

January 8, 2026

Calls in 2026

Decks in 2026